BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Medicamen Biotech Ltd. Share Price

NSE
BSE

NSE : MEDICAMEQ

BSE : 531146

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

₹264.15

High

₹281.60

Price Summary

Previous Close ₹266.85
Day's Range ₹264.15 - ₹281.60
Open ₹277.00
52 Week Range ₹216.95 - ₹448.80
Volume 13,292
Market Cap ₹0.00

Stocks Summary

Trade Value ( ₹ in Lacs) 36.25
Market Cap (₹ in Mn) 0.00
Dividend Yield(%) 0.37
Price/Earning (TTM) 38.55
TTM EPS (₹) 6.95
P/E Ratio 93.43
Book Value(₹) 1.34
PAT Margin (%) 4.03
Face Value (₹) 10.00
ROCE(%) 5.77

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 411.42 1723.86
Expenses N/A N/A
PBT 34.78 168.88
Operating profit 0.0 0.0
Net profit 25.23 132.98

Shareholding Pattern

Promoters (% Holding)

40.46%

Mutual funds (% Holding)

0.00%

Non-Institution (% Holding)

59.39%

FI/Banks/Insurance (% Holding)

0.00%

Government (% Holding)

0.05%

FII

0.10%

About Medicamen Biotech Ltd.

Founded 1993
NSE Symbol MEDICAMEQ

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,53,750.23 1,891.15 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 1,82,116.76 6,856.20 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,51,313.88 4,474.05 3,102.00 - 3,102.00
Apollo Hospitals Enterprise Ltd. 1,19,400.22 8,313.00 6,696.50 - 6,696.50
Cipla Ltd. 1,13,225.36 1,401.65 1,165.70 - 1,165.70
Dr. Reddy's Laboratories Ltd. 1,10,037.00 1,319.00 1,148.40 - 1,148.40
Max Healthcare Institute Ltd. 1,06,234.43 1,091.55 903.00 - 903.00
Lupin Ltd. 1,04,489.83 2,287.25 1,836.80 - 1,836.80
Zydus Lifesciences Ltd. 1,04,265.97 1,036.20 835.50 - 835.50
Mankind Pharma Ltd. 1,03,844.60 2,506.70 1,909.70 - 1,909.70
no-content No Records Found

Latest News

May
20
2026
EQUITY Posted on May 20th 2026

Medicamen Biotech informs about board meeting

Pursuant to Regulation 29 read with Regulation 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), Medicamen Biotech has informed that a Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, May 27, 2026 at the registered office of the Company situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 to consider and approve the following business(s): 1. The Audited Financial Results of the Company (Standalone and Consolidated) for the quarter / year ended on March 31, 2026 2. To consider the recommendation of Final Dividend on Equity Shares of the Company for the financial year 2025-26, if any. 3. To consider and appoint SPB & Co, Cost Accountants, as the Cost Auditor of the company for the financial year 2026-27. 4. To consider and appoint Cheena & Associates, as the Internal Auditor of the company for the financial year 2026-27. 5. Any other business with the permission of the chair. Further, in accordance with the SEBI (Prevention of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the Company's securities was closed from April 1, 2026 and will open 48 hours after the said Financial Results are declared to Stock Exchanges.

.The above information is a part of company’s filings submitted to BSE.

Read More
May
21
2026
EQUITY Posted on May 21st 2026

Lenskart Solutions informs about outcome of board meeting

Lenskart Solutions has informed that the Board of Directors of the Company at its meeting held today, May 20, 2026, has, considered the following matters: Approved the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended March 31, 2026 (Financial Results) as recommended by the Audit Committee of the Board of the Company and took on record the Auditor’s Report(s) with unmodified opinions on the Financial Results issued by the Statutory Auditors of the Company. Pursuant to Regulation 33 of the SEBI Listing Regulations, we are enclosed the following as Annexure - 1; Approved the unaudited Proforma Financial Statements of Profit and Loss for the quarter and financial year ended March 31, 2026, enclosed as Annexure - 2. These financial statements reflect the comparative numbers for corresponding periods on account of acquisitions made by the Company in the last 12 months to enable a like-for-like comparison, prepared by the Management and not subject to review/audit.
The above information is a part of company’s filings submitted to BSE.
Read More
May
21
2026
EQUITY Posted on May 21st 2026

Lenskart Solutions informs about press release

Lenskart Solutions has informed that it enclosed the Newspaper clippings published in the Financial Express (English) and Jansatta (Hindi) editions of May 21, 2026, wherein Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026 have been published. The above information will also be hosted on the Company’s website at https://www.lenskart.com/corporate/investorrelations
The above information is a part of company’s filings submitted to BSE.
Read More
May
21
2026
EQUITY Posted on May 21st 2026

Sai Life Sciences informs about earnings call transcript

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, Sai Life Sciences has attached the transcript of the Earnings Call for Audited Financial Results of the Company for the quarter and year ended 31 March 2026 held on Friday, 15 May 2026, at 04:00 PM (IST). The transcript is uploaded on company’s website on below link: Earnings-Call-Transcript.pdf
The above information is a part of company’s filings submitted to BSE.
Read More
May
21
2026
EQUITY Posted on May 21st 2026

Kaya informs about press release

Kaya has informed that it enclosed Newspaper Publication of the audited Consolidated Financial Results for the quarter and financial year ended March 31, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Medicamen Biotech Ltd. ?

The current share price of Medicamen Biotech Ltd. is ₹266.85 as of 2026-05-21.

The market capitalisation of Medicamen Biotech Ltd. is ₹363.28 as of 2026-05-21.

The 1-year return of Medicamen Biotech Ltd. is 0.00% as of 2026-05-21.

The P/E ratio of Medicamen Biotech Ltd. is 93.43 as of 2026-05-22.

The 52-week high and low of Medicamen Biotech Ltd. are ₹448.80 and ₹216.95, respectively, as of 2026-05-21.

The dividend yield of Medicamen Biotech Ltd. is 0.3733% as of2026-05-21.

You can buy Medicamen Biotech Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Medicamen Biotech Ltd. is .

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore